890846--5/28/2010--UROPLASTY

related topics

{product, liability, claim}

{product, market, service}

{stock, price, share}

{property, intellectual, protect}

{personnel, key, retain}

{acquisition, growth, future}

{customer, product, revenue}

{product, candidate, development}

{cost, regulation, environmental}

{operation, international, foreign}

{control, financial, internal}

{stock, price, operating}

{loss, insurance, financial}

{capital, credit, financial}

{condition, economic, financial}

We cannot predict how quickly or how broadly the market will accept our products. If we are not able to attract, retain and motivate our sales force and expand our distribution channels, our sales and revenues will suffer. The size and resources of our competitors may render it difficult for us to successfully compete in the marketplace. We are primarily dependent on sales of two product lines and our business would suffer if sales of either of these product lines decline. We likely will require additional financing and may find it difficult to obtain the financing on favorable terms, or at all. We could be subject to fines and penalties, or required to temporarily or permanently cease offering products, if we fail to comply with the extensive regulations applicable to the sale and manufacture of medical products. We may be subject to changing federal regulation that increases the cost of doing business or imposes requirements with which we cannot comply. Our distributors may not obtain regulatory in a timely basis, or at all. If third parties claim that we infringe upon their intellectual property rights, we may incur liabilities and costs and may have to redesign or discontinue selling the affected product. If we are unable to adequately protect our intellectual property rights, we may not be able to compete effectively. Product liability claims could adversely affect our business and results of operations. The loss or interruption of materials from any of our key suppliers could delay the manufacture of our products, which would limit our ability to generate sales and revenues. If we are not able to maintain sufficient quality controls, regulatory approvals of our products by the European Union, Canada, the FDA or other relevant authorities could be delayed or denied and our sales and revenues will suffer. If we are not able to acquire or license other products, our business and future growth prospects could suffer. Our business strategy relies on assumptions about the market for our products, which, if incorrect, would adversely affect our business prospects and profitability. Recent deterioration in the economy and credit markets may adversely affect our results of operations and our plans for expansion. Negative publicity regarding the use of silicone material in medical devices could harm our business and result in a material decrease in revenues. We derive a significant portion of our sales from outside of the United States and are subject to the risks of international operations. If we lose the services of our chief executive officer or other key personnel, we may not be able to manage our operations and meet our strategic objectives. Our stock is thinly traded and you may find it difficult to sell your investment in our stock at quoted prices. Our stock price may fluctuate and be volatile. Future sales of our common stock in the public market could lower our share price. We will be exposed to risks relating to evaluations of controls required by Section 404 of the Sarbanes-Oxley Act.

Full 10-K form ▸

890846--5/28/2010--UROPLASTY_INC